Program
Anti-BTN3A Agonistic Monoclonal Antibody ICT01
Also written as “IPN60340 + azacitidine + venetoclax”, “IV ICT01” and “ICT01”.
Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms, led by Ipsen.
Drug pageAnti-BTN3A Agonistic Monoclonal Antibody ICT01: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since May 28, 20263 company-led studies, 2 open or runningNext primary completion: Oct 15, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsen | 32 open or running | phase 3since May 28, 2026 | Jan 24, 2020 | Oct 15, 2027phase 2 · NCT04243499 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2020First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT04243499 · 293 enrolled · United States, Belgium, France and more
- Mar 24, 2022Phase 2 study in Solid Tumor, AdultNCT05307874 · 56 enrolled · France, Germany, United Kingdom
- May 28, 2026Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07623187 · 540 planned
Ahead
- Oct 15, 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT04243499
- May 31, 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07623187
TargetBeta
BTN3A1 →read by rule
“A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623187Leukemia, Myeloid, Acute | 3 | Not yet recruiting | May 31, 2031 | 540 |
| NCT05307874Solid Tumor, Adult · France, Germany, United Kingdom | 2 | Terminated | Oct 9, 2025 | 56 |
| NCT04243499Hematologic Neoplasms · United States, Belgium, France and more | 2 | Active, not recruiting | Oct 15, 2027 | 293 |
How it is read
Names in the registry
- “IPN60340 + azacitidine + venetoclax”, 1 entry
- “IV ICT01”, 1 entry
- “ICT01”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.